Eiko Lifesciences Allots 1.5 Lakh Equity Shares on Warrant Conversion
FUNDRAISE
▲ Positive Development
LOW RISK
📅 Filed on BSE: 16 Oct 2026, 07:32 PM IST · BSE ID: 8be520af-af2f-4cd0-9a3b-dd23588b3433
View Original BSE Filing (PDF)
💡
In Simple Terms
The company issued new shares by converting warrants held by a promoter, increasing its total share capital.
🤖 AI Summary
- Eiko Lifesciences allotted 1,50,000 equity shares on warrant conversion.
- Allotment completed at Rs. 55 per share, including Rs. 45 premium.
- Lenus Finvest Private Limited, a promoter, converted warrants.
- Company's paid-up equity share capital increased to Rs. 14,80,08,540.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Number of Warrants Converted
1,50,000
Issue Price per Equity Share
Rs. 55/-
Premium per Equity Share
Rs. 45/-
Amount Received (75% of Issue Price)
Rs. 61,87,500/-
Total Issued, Subscribed and Paid-up Equity Share Capital
Rs. 14,80,08,540/-
Total Equity Shares Outstanding
1,48,00,854
🏢 How This Affects the Company
The conversion of warrants into equity shares increases the company's paid-up share capital by Rs. 1,50,00,000 (1,50,000 shares x Rs. 10 face value). The premium received adds to reserves.
This issuance dilutes existing shareholder equity per share but strengthens the company's capital base. No new operational risks are immediately apparent from this filing.
👥 What This Means For Shareholders
✅
Action Required
No action is required from existing shareholders regarding this allotment.
👤
Who Is Affected
Existing shareholders are affected by a fractional increase in the total number of equity shares, leading to a slight dilution of their percentage ownership.
🔍
Management Signal
Management is executing on previous capital raising plans and strengthening the company's equity structure through warrant conversions.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Next quarterly results for updated shareholding patterns.
Company announcements regarding use of capital raised via warrants.
Any further corporate actions or issuances planned by the company.
LOW RISK
Routine capital raising event via warrant conversion, no new material risks identified.
💡 Investor Takeaway
Eiko Lifesciences allotted 1,50,000 equity shares at Rs. 55 each on warrant conversion, raising Rs. 61,87,500 (75% payment), increasing paid-up capital to Rs. 14,80,08,540.
⚖️ Strengths & Concerns
✅ Positives
- Completed conversion of 1,50,000 warrants into equity shares at Rs. 55 per share.
- Increased issued, subscribed, and paid-up equity share capital to Rs. 14,80,08,540.
📅 Company Track Record
Eiko Lifesciences Limited was incorporated in 1977. This filing is the first material event disclosed on BSE for this company in our records.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
How many equity shares did Eiko Lifesciences allot on warrant conversion?
Eiko Lifesciences allotted 1,50,000 equity shares upon the conversion of warrants.
What was the issue price for the new equity shares allotted by Eiko Lifesciences?
The issue price for the new equity shares was Rs. 55/- each, including a premium of Rs. 45/-.
Who was the allottee for these converted warrants in Eiko Lifesciences?
Lenus Finvest Private Limited, a promoter entity, was the allottee for these converted warrants.
How much did Eiko Lifesciences' paid-up equity share capital increase?
The company's paid-up equity share capital increased to Rs. 14,80,08,540/- following the allotment.
What amount was received by Eiko Lifesciences for the warrant conversion?
The company received Rs. 61,87,500/-, which represents 75% of the issue price per warrant.
Questions based on this BSE filing only. For information purposes.